Search Results

By Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, Ronald Hoffman, MD, Jason Gotlib, MD, Rami Komrokji, MD, and Hagop M. Kantarjian, MD  / December 15, 2012

Updates on Ruxolitinib from ASCO and ASH 2012, including Long-term Survival Data

Ruxolitinib (Jakafi), a novel, oral JAK1 and JAK2 inhibitor, was approved by the FDA on November 16, 2011 for patients with intermediate- or high-risk myelofibrosis. The approval was based on its efficacy in reducing spleen size and improving disease-related burdensome symptoms. In the brief In the ...